Department of Pharmacology and Therapeutics, College of Medicine, University of Kufa, Iraq , maysamawadh2@gmail.com
Abstract (143 Views)
Background:
Leishmaniasis is a parasitic disease caused by the Leishmania parasite, transmitted to humans through the bite of an infected sand-fly. The disease manifests in four primary clinical manifestations: visceral, cutaneous, diffuse cutaneous, and post-kalaazar dermal. The disease's clinical manifestations depend on the Leishmania species and their immune response. Current antileishmanial drugs include amphotericin B, antimonials, sitamaquine, pentamidine, paromomycin, and miltefosine. However, these drugs have drawbacks, such as resistance to pentavalent antimonials and nephrotoxicity. The World Health Organization suggests using plants as a healing agent with good efficacy and affordability. Conyza Canadensis, a biennial plant, has been used for wound healing and has shown efficacy against gram-positive and gram-negative bacteria
Objective: The study aimed to investigate the anti-leishmanial activity of extracts from Conyza Canadensis, an Iraqi strain of Leishmania tropica.
Material and method : The phytochemical compounds were found in the extraction process, with total alkaloid content, phenolic compounds, flavonoid content, amino acid analysis, and total glycosides. The extract was prepared into stock solutions and sub-cultured in RPMI-1640. The cells were then incubated in tissue culture flasks and treated with different concentrations of SSG and aqueous/alcoholic extracts. The anti-leishmanial activity of the extracts was then evaluated using the sandwich enzyme-linked immunosorbent assay (ELISA) technique. The results showed that the extracts had anti-leishmanial activity.
Result: the study shows that Iraqi C. canadensis plant extract contains alkaloids, gallic acid, apigenin, chlorogenic acid, caffeineic acid, quercetin, p-cumaric acid, and GSH, which reduce neopterin levels and activate immune response against L. tropica.